In Reply: In response to Dr Gitelman and colleagues, most of the 160 screened patients were not eligible for the study either because of disease diagnosed for more than 6 weeks, absence of positive results from an anti–glutamic acid decarboxylase test, presence of previous ketoacidosis, or absence of evaluation for ketoacidosis. Approximately 30% of the patients eligible for the study were not willing to accept the risks of the procedure.
We performed weekly monitoring for cytomegalovirus infection in all patients. None of them developed primary infection or reactivation of cytomegalovirus or Epstein-Barr virus. We support research efforts to expand on our work on immune intervention in type 1 diabetes mellitus, with a goal of obtaining the same or better results with less toxicity.
Voltarelli JC, Martinez EZ, Burt RK. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus—Reply. JAMA. 2009;302(6):624-625. doi:10.1001/jama.2009.1100